Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 16/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896615 | 0.87 | AKR1C3 (0.46) | TRPM8AKR1C3AKR1C2 | |
| SCHEMBL27659750 | 0.79 | TRPM8 (0.43) | TRPM8CTNNB1WNT3A | |
| SCHEMBL666127 | 0.79 | PLAU (0.40) | MAPK1CTNNB1WNT3A | |
| Bromide SCHEMBL27659823 | 0.78 | TRPM8 (0.42) | TRPM8CTNNB1WNT3A | |
| SCHEMBL4162406 | 0.78 | TRPM8 (0.37) | TRPM8 | |
| SCHEMBL3954421 | 0.78 | DPP8 (0.39) | — | |
| SCHEMBL2699407 | 0.76 | CNR2 (0.44) | POLBMAPK1AKR1C3AKR1C2 | |
| SCHEMBL4036425 | 0.75 | PLAU (0.44) | POLBMAPK1 | |
| SCHEMBL14519455 | 0.75 | TRPM8 (0.42) | TRPM8POLBMAPK1CTNNB1WNT3A | |
| SCHEMBL895488 | 0.74 | ALDH1A1 (0.44) | TRPM8POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-7618993-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-11-17 | — | — | US | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286202-A1 | New Compounds | REN, PCSK9, FURIN | TRPM8 352/4885POLB 2337/4885MAPK1 3756/4885 |
| US-20080171770-A1 | Compounds | REN, PCSK9, SLC10A1 | TRPM8 336/4885POLB 2234/4885MAPK1 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.